John, Mike & Tom's <b>Wild World of Stocks</b> Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : John, Mike & Tom's Wild World of Stocks

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: John Pitera who wrote ()	3/15/2000 9:34:00 AM
From: wlheatmoon	Read Replies (1) of 2850

analysts to AMGN's rescue... Wednesday March 15, 9:15 am Eastern Time RESEARCH ALERT - Amgen raised NEW YORK, March 15 (Reuters) - Credit Suisse First Boston on Wednesday said analyst Alex To raised his rating of biotechnology giant Amgen Inc. (NasdaqNM:AMGN - news) to strong buy from buy. -- said set 12-month price target of $105 share. -- said Tuesday's biotech skid ``presents a nice entry point on AMGN.'

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next